Skip to main content
Amanda Guidon, MD, Neurology, Boston, MA

AmandaColemanGuidonMD

Neurology Boston, MA

Neuromuscular Medicine

Physician

Dr. Guidon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Guidon's full profile

Already have an account?

  • Office

    165 Cambridge St
    Ste 820
    Boston, MA 02114
    Phone+1 855-644-6387
    Fax+1 617-726-2019

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Neuromuscular Medicine (Neurology), 2012 - 2013
  • Duke University Hospital
    Duke University HospitalFellowship, Neuromuscular Medicine (Neurology), 2011 - 2012
  • Duke University Hospital
    Duke University HospitalResidency, Neurology, 2008 - 2011
  • Duke University Hospital
    Duke University HospitalInternship, Internal Medicine, 2007 - 2008
  • University of Rochester School of Medicine and Dentistry
    University of Rochester School of Medicine and DentistryClass of 2007

Certifications & Licensure

  • ME State Medical License
    ME State Medical License Current
  • MA State Medical License
    MA State Medical License 2013 - 2025
  • NC State Medical License
    NC State Medical License 2007 - 2014
  • American Board of Psychiatry and Neurology Neurology
  • American Board of Psychiatry and Neurology Neuromuscular Medicine
  • American Board of Electrodiagnostic Medicine (ABEM)

Publications & Presentations

PubMed

Press Mentions

  • Myasthenia Gravis: Where Does Traditional Therapy Fit In?
    Myasthenia Gravis: Where Does Traditional Therapy Fit In?November 4th, 2024
  • “Chemical Plasmapheresis” Drug for Myasthenia Gravis Is Safe, Lowers Antibodies, and Produces Hints of Efficacy in Phase 2 Trial
    “Chemical Plasmapheresis” Drug for Myasthenia Gravis Is Safe, Lowers Antibodies, and Produces Hints of Efficacy in Phase 2 TrialJuly 11th, 2019
  • Myasthenia Gravis: Framingham Resident Lives with Rare Disease
    Myasthenia Gravis: Framingham Resident Lives with Rare DiseaseJune 24th, 2019